Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Novartis AG and Novartis Pharmaceuticals Canada Inc. v. RhoxalPharma Inc. and the Minister of Health

Reading Time 1 minute read Subscribe


Proceedings to prohibit the Minister of Health from issuing a notice of compliance which would allow the sale, by RhoxalPharma, of a generic version of cyclosporine, a drug used to prevent transplant rejection. The patent at issue covered a pharmaceutical formulation containing cyclosporine in the form of a hydrosol. The application was eventually dismissed. RhoxalPharma was advised in these proceedings by a team from Fasken Martineau that included Marie Lafleur and Martin Sheehan. For more information, see (2004) FC 474 and (2005) FCA 11.



    Receive email updates from our team